Navigation Links
ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
Date:3/18/2008

ADDISON, Texas, March 18 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) announced today that Kerry P. Gray, the company's President and Chief Executive Officer, will provide a corporate presentation at the Cowen and Company 28th Annual Health Care Conference in Boston, MA on March 20, 2008 at 11:00 a.m. Eastern time.

Interested investors and others may also listen to the presentation, hosted by Cowen and Company, live and by replay at http://www.corporateir.net/ireye/conflobby.zhtml?ticker=ULU&item_id=1780912 and clicking on the link for this webcast. Access to the webcast is not password protected.

About ULURU Inc.:

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company

Kerry P. Gray

President & CEO

Terry K. Wallberg

Vice President & CFO

(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
2. ULURU Inc. Reports Third Quarter 2007 Results
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. ULURU Inc. Announces Odd-Lot Buy Back Offer
5. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
6. Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference
7. Smart Balance to Webcast Presentation at Citi Small/Midcap Conference
8. Julia Quinlan to present awards at a conference hosted by Rutgers College of Nursing
9. Transition Therapeutics to Present at Cowen & Company 28th Annual Healthcare Conference
10. Covance to Present at Lehman Brothers 11th Annual Global Healthcare Conference
11. Hologic to Present at Lehman Brothers Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...ONT, Calif., May 12 /PRNewswire/ -- Keck Graduate ...008, commencement ceremony will feature,the gradua...tudent, Eric,Tan, and the unveiling of KGI,s first... of Eric,s achievement in becoming the,first gradu..., KGI,s senior,vice president for academic affairs...
(Date:5/12/2008)... VA Nurses Are ,the Compassionate Heart, of System... The Department of,Veterans Affairs (VA), the nati...ional Nurses Week by honoring six of its top profe...rt of VA,s world-class health care,system," stated... "A great,deal of our reputation comes from the pe...
(Date:5/12/2008)... NASDAQ: CRME TSX: COM, VANCOUVER...Corp.,(NASDAQ: CRME / TSX: COM) today announced th...quarter of 2008 on the afternoon of Tuesday, May 1...and webcast at 4:30pm,Eastern (1:30pm Pacific) on ...onference call, please dial 416-641-6117 or,866-29...
(Date:5/12/2008)...lease is available in French . , Montreal, May...n that the administration of sildenafil protects t... This study was led by Dr. Christine Des Rosiers f...t Institute, in collaboration with Dr. Basil Petro...ty Health Centre (MUHC) and Dr. Christian Deschepp...
Breaking Medicine News(10 mins):Health News:KGI 2008 Commencement Features First PhD Graduate, Biotech Painting 2Health News:Cardiome To Release 2008 First Quarter Results 2Health News:Cardiome To Release 2008 First Quarter Results 3Health News:Cardiome To Release 2008 First Quarter Results 4Health News:New approach to protect the hearts of patients with muscular dystrophy 2Health News:New approach to protect the hearts of patients with muscular dystrophy 3
...rley Street plastic surgeon plans to sell a contro...de him and his wife “look years younger”.// He as... his memory and removed wrinkles, and made his wif... enough to be his daughter. The plastic surgeon a...
... respiratory specialists declared yesterday that c...million annually.// Lost of productivity when suf...n, while the health service industry loses ?104mil...itish Thoracic Society (BTS), this figure does not...
...y known as Mandrax, is a "downer" used to get reli...ide effects, however, have led to the banning of t...roduced in the 1960s into the pharmaceutical marke...was also used for other medicinal uses, especially...
... claimed to prevent more sudden deaths than defibr...ted defibrillators according to US scientists.// R... compared such preventive strategies by food suppl...n a computer-simulated community of 100,000 people...
Other Medicine News:Health News:Look younger with HGH!! 2Health News:Delhi Police Seized 4,400 kg of Banned Drug Mandrax 2
(Date:5/8/2008)...IELD, Ill., May 8 /- Siemen...(R) Holdings (LabCorp(R)) today announced,that the...s future,possibilities to co-develop new clinical ...tics, metabolic syndrome, oncology and diabetes. U... on developing new tests that,could make the bigge...
(Date:5/8/2008)...AVEN, Conn., May 8 /- VION ...nced the start of an investigator-sponsored,Phase ...loretazine(R),(VNP40101M) in combination with cyta...ed acute myelogenous leukemia (AML) and high-risk,...g conducted under the,direction of Ellen K. Ritchi...
(Date:5/8/2008)...Data Presentations to Focus on Use of Pro-Healing ...lerate Dual-Antiplatelet Therapy, HONG KONG, May ... both,a randomized pilot study and the real-world ... R stent, the world,s first pro-healing stent, wil... 2008 in Barcelona, Spain., The symposium, titled...
(Date:5/8/2008)...NGTON, Del., May 8 /- Astra...of a supplemental New Drug Application,(sNDA) to t...OQUEL XR(TM),(quetiapine fumarate) Extended-Releas...neralized anxiety disorder (GAD), including mainte...approval has been sought for an,atypical antipsych...
Breaking Medicine Technology:Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Depression and Alzheimers Risk Linked 16158 1Depression and Alzheimers Risk Linked 16158 2Depression and Alzheimers Risk Linked 16158 3War between the sexes begins before twins birth TAU researchers say 2794 1War between the sexes begins before twins birth TAU researchers say 2794 2U Iowa study finds biological link between pain and fatigue 2792 1U Iowa study finds biological link between pain and fatigue 2792 25W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation 16157 15W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation 16157 25W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation 16157 3
... symptoms of SLE,disease at 52 Weeks and demonstra... weeks-, ROCKVILLE, Md., June 14, 2007 /PRNewswire...nnounced the presentation of Phase 2,trial data de...ficantly reduced disease activity across multiple ... quality of life in,patients with active systemic ...
...- CombinatoRx,Incorporated (NASDAQ: CRXX) today a...ed to its immuno-inflammatory product,candidates, ...t,Rheumatism (EULAR) Annual Congress of Rheumatolo... CRx-102 , In a poster entitled "Inhibition of Mac...CRx-102, a Novel Synergistic Combination,Drug Cand...
Other Medicine Technology:Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 2Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 3Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 4
Supplied sterile in peel-open packages. Intended for one-time use.
Used for catheter positioning and exchange in endourological procedures. The increased inner diameter of the wire guide coils allows utilization of an extra heavy duty mandril with a smooth transitio
Supplied sterile in peel-open packages. Intended for one-time use.
...nitial access wire into the renal pelvis through a... The mandril type shaft construction provides rigi....89 mm) diameter wire guide. The distal portion of...r the tapered mandril which provides tip flexibili...
Medicine Products: